Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbvie’s Elagolix Looks Set To Stake Claim In Endometriosis

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbvie plans 2017 filing for elagolix, licensed from Neurocrine, after second Phase III trial leaves the oral drug with a competitive profile.

You may also be interested in...



AbbVie's Elagolix May Be Cost Effective, But Will Test Health Budgets – ICER

Third-party value assessment organization says AbbVie/Neurocrine's elagolix would be cost effective for endometriosis and associated pain, using a placeholder price of $7,000 per year. But the cost would be substantial for health budgets given the broad prevalence of the condition. 

Making A Market In Women’s Health: Endometriosis, Fibroids Emerge As Rx Targets

Candidates like AbbVie’s elagolix and Actavis’ Esmya promise oral therapy without the drawbacks of the artificial menopause induced by available hormone suppression therapy – and may pave the way for newer approaches while expanding the market.

AbbVie Sets Out To Win Over Investors In Its First Financial Call

Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel